Cargando…

Interplay between the Gut Microbiota and Inflammatory Mediators in the Development of Colorectal Cancer

SIMPLE SUMMARY: The development of colorectal cancer (CRC) can be affected by various inflammatory mediators, such as tumor necrosis factor, nuclear factor kappa B, interleukins, and interferons. Moreover, these inflammatory mediators can be reciprocally affected by gut microbiota. This review demon...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Gwangbeom, Lee, Yunna, Im, Eunok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916585/
https://www.ncbi.nlm.nih.gov/pubmed/33578830
http://dx.doi.org/10.3390/cancers13040734
Descripción
Sumario:SIMPLE SUMMARY: The development of colorectal cancer (CRC) can be affected by various inflammatory mediators, such as tumor necrosis factor, nuclear factor kappa B, interleukins, and interferons. Moreover, these inflammatory mediators can be reciprocally affected by gut microbiota. This review demonstrates the correlation of gut microbiota, inflammatory mediators, and CRC by summarizing studies with germ-free animals, antibiotic-treated animals, fecal microbiota transplantation, administration of specific microbiota, transgenic mice, and experimental models of CRC. It is clear that gut microbiota affect CRC through inflammatory mediators, though whether they promote or inhibit CRC depends on the context. Therefore, modulation of gut microbiota can be a good strategy for CRC prevention and control or be adjunctive therapy for CRC. ABSTRACT: Inflammatory mediators modulate inflammatory pathways during the development of colorectal cancer. Inflammatory mediators secreted by both immune and tumor cells can influence carcinogenesis, progression, and tumor metastasis. The gut microbiota, which colonize the entire intestinal tract, especially the colon, are closely linked to colorectal cancer through an association with inflammatory mediators such as tumor necrosis factor, nuclear factor kappa B, interleukins, and interferons. This association may be a potential therapeutic target, since therapeutic interventions targeting the gut microbiota have been actively investigated in both the laboratory and in clinics and include fecal microbiota transplantation and probiotics.